Abstract
Despite advances in antiemetic therapy, chemotherapy-induced nausea and vomiting (CINV) remains the most feared and expected side effect of chemotherapy. Optimization of antiemetic therapy is important because CINV can lead to reduced quality of life, increased use of health care resources, and compromised treatment adherence. The evidence illustrates how antiemetic recommendations have evolved and raises ongoing issues and controversies in the management of CINV.